Nabiximols, an oromucosal spray of a complete cannabis plant extract that has a one:1 ratio of THC to cannabidiol (CBD), was originally licensed and approved in Europe, the United Kingdom, and Canada with the treatment of agony and spasticity associated with various sclerosis (GW Pharmaceuticals, 2016; Pertwee, 2012), nevertheless it carries on to